Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy

Rachel E. Lewis, Emily A. Towery, Sneha G. Bhat, Andrew J. Ward, Robert E. Heidel, Kendall M. Bielak, Hannah E. Simpson, James M. McLoughlin, James M. Lewis

Research output: Contribution to journalArticle

Abstract

Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6%), squamous cell carcinoma in 61 (26.8%), and basal cell carcinoma in 28 (12.2%) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6%). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.

Original languageEnglish (US)
Pages (from-to)1056-1060
Number of pages5
JournalAmerican Surgeon
Volume85
Issue number9
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Acellular Dermis
Skin Neoplasms
Transplants
Skin
Neoplasms
Tissue Donors
Artificial Skin
Skin Transplantation
Basal Cell Carcinoma
Wounds and Injuries
General Anesthesia
Squamous Cell Carcinoma
Melanoma
Demography
Morbidity

ASJC Scopus subject areas

  • Surgery

Cite this

Lewis, R. E., Towery, E. A., Bhat, S. G., Ward, A. J., Heidel, R. E., Bielak, K. M., ... Lewis, J. M. (2019). Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy. American Surgeon, 85(9), 1056-1060.

Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy. / Lewis, Rachel E.; Towery, Emily A.; Bhat, Sneha G.; Ward, Andrew J.; Heidel, Robert E.; Bielak, Kendall M.; Simpson, Hannah E.; McLoughlin, James M.; Lewis, James M.

In: American Surgeon, Vol. 85, No. 9, 01.01.2019, p. 1056-1060.

Research output: Contribution to journalArticle

Lewis, RE, Towery, EA, Bhat, SG, Ward, AJ, Heidel, RE, Bielak, KM, Simpson, HE, McLoughlin, JM & Lewis, JM 2019, 'Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy', American Surgeon, vol. 85, no. 9, pp. 1056-1060.
Lewis, Rachel E. ; Towery, Emily A. ; Bhat, Sneha G. ; Ward, Andrew J. ; Heidel, Robert E. ; Bielak, Kendall M. ; Simpson, Hannah E. ; McLoughlin, James M. ; Lewis, James M. / Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy. In: American Surgeon. 2019 ; Vol. 85, No. 9. pp. 1056-1060.
@article{adb6ea74b00548ed94897cee3c7ce579,
title = "Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy",
abstract = "Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6{\%}), squamous cell carcinoma in 61 (26.8{\%}), and basal cell carcinoma in 28 (12.2{\%}) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6{\%}). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.",
author = "Lewis, {Rachel E.} and Towery, {Emily A.} and Bhat, {Sneha G.} and Ward, {Andrew J.} and Heidel, {Robert E.} and Bielak, {Kendall M.} and Simpson, {Hannah E.} and McLoughlin, {James M.} and Lewis, {James M.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "85",
pages = "1056--1060",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "9",

}

TY - JOUR

T1 - Human acellular dermal matrix is a viable alternative to autologous skin graft in patients with cutaneous malignancy

AU - Lewis, Rachel E.

AU - Towery, Emily A.

AU - Bhat, Sneha G.

AU - Ward, Andrew J.

AU - Heidel, Robert E.

AU - Bielak, Kendall M.

AU - Simpson, Hannah E.

AU - McLoughlin, James M.

AU - Lewis, James M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6%), squamous cell carcinoma in 61 (26.8%), and basal cell carcinoma in 28 (12.2%) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6%). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.

AB - Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6%), squamous cell carcinoma in 61 (26.8%), and basal cell carcinoma in 28 (12.2%) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6%). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.

UR - http://www.scopus.com/inward/record.url?scp=85072920807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072920807&partnerID=8YFLogxK

M3 - Article

C2 - 31638524

AN - SCOPUS:85072920807

VL - 85

SP - 1056

EP - 1060

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 9

ER -